COPD Protocol Guidance: 3 applications of 1 unit IV and 1 unit NEB
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Proactive Regeneration II – High-Stress Lifestyle
Proactive Regeneration II Protocol Guidance: 1 application of 2 units IV monthly or bi-monthly
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Proactive Regeneration I – Common Lifestyle
Specialties > Proactive Regeneration > Common Lifestyle
Proactive Regeneration I Protocol Guidance: 1 application of 1 unit IV monthly
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Wrist Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Shoulder Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Lumbar Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Knee Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hip Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hand Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ganglion Impair Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Foot Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Elbow Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Cervical Disks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ankle Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Macular Degeneration Protocol Guidance: 3 applications of 2 units IV and 1 unit IN
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Traumatic Brain Injury Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Stroke Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Spinal Cord Injury Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Peripheral Neuropathy Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Depression/Addiction/Detox Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Neurodegenerative Disorder Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Cervical Discs Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Wounds Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ulcers Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Neck Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Leg Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Skin Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hair Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Face Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Burns Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Anti-Aging Protocol Guidance: 1 application of 2 units IV not less often than monthly
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Arm Protocol Guidance: 1 application of 2 units IV not less often than monthly
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Wrist Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Shoulder Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Lumbar Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Knee Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hip Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hand Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ganglion Impair Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Foot Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Elbow Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Cervical Disks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ankle Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Vasculature Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Myocardial Infarction Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Peripheral Arterial Disease Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
</ul class=”cutome-font”>
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Peripheral Neuropathy Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Parkinson’s Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Thyroid Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Rheumatoid Arthritis Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Multiple Sclerosis Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Irritable Bowel Syndrome Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Hashimoto’s Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Fibromyalgia Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Diabetes Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Autism (Non-Acute) Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Crohn’s Protocol Guidance: 4 applications of 2 units IV
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Autism (Acute) Protocol Guidance: 4 applications of 2 units IV
*Lumbar puncture for severe older patients
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Ganglion Impair Protocol Guidance: 3 applications of 4cc IV and 4cc IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Lumbar Protocol Guidance: 3 applications of 4cc IV and 4cc IA
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
